1. Marx. T. L. and Mehta. A.E.(2003). Polycystic ovary syndrome: pathogenesis and treatment over the short and long term. Cleve.Clin.j.Med.70(1):31-41
2. Guyton, A.C. and Hall, J.E. (2001). Female Physiology before pregnancy;and the female hormones. In: Medical Physiology. Guyton, A.C. and Hall, J.E. (eds.). W.B. Saunders Company. Philadelphia. Pp 929-943.
3. King. J. (2006) .Polycystic Ovary Syndrome. Journal of Midwifery & Women’s Health. 51(6):1-3.
4. Tsilchorozidou,T., Overton, C., and Conway, G.S.(2004). The pathophysiology of polycystic ovary syndrome. Clin. Endocrinol.60:1–17.
5. Ehrmann, D. A. (2005). Polycystic ovary syndrome. Nat. Engl. J .Med. 352:1223–1236
6. Guzick , D.S.( 2004). Polycystic ovary syndrome. Obstet. Gynecol. 103:181–193.
7.Hill ,K.M. (2003): The pathogenesis and treatment of PCOS. Nurse Pract. 28: 8-25.
8. Azziz, R., Ochoa, T.M., Bradley, E.L., Potter, H. D., Boots, L.R. (1995). Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J. Clin. Endocrinol. Metab; 80:3406-3411.
9.Gilling-Smith, C., Willis, D.S., Beard, R.W., and Franks, S. (1994). Hypersecretion of and rostenedione by isolated thecal cells from polycystic ovaries. J. Clin .Endocrinol. Metab. 79:1158-1165.
10. Kiddy, D. S., Sharp, P.S., White, D.M., Scanlon, M.F., Mason, H.D., Bray, C.S., and Franks, S. (1990). Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin. Endocrinol.(Oxf) 32:213–220.
11. Macklon, N.S., and Fauser, B.C.(2000). Regulation of follicle development and novel approaches to ovarian stimulation for IVF. Hum. Reprod. Update 6(4):307-312.
12. Mulders ,A., Laven, J., Visser ,J.,Themmen, A., Jong, F., and Fauser, J.M. (2005). Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endo. Metab. 89(1):318-323.
13. Flegal, K. M., Graubard, B. I., Williamson, D. F., and Gail, M. H. (2005). Excess deaths associated with underweight, Overweight, and Obesity. J. American Med. Assoc. 293(15):1861-1867
14. Dewhurst, A.(1999). Textbook of Obstetrics and Gynaecology for Postgraduates. 7th edition. Page 52, chapter 6.
15. Bronstein , J., Tawdekar, S ., Liu, Y., Pawelczak, M., David, R ., and Shah ,B. (2011). Age of Onset of Polycystic Ovarian Syndrome in Girls May Be Earlier Than Previously Thought. J .Pediatr. Adolesc. Gynecol.24:15-20
16. Chang, R. J. and Katz, S.E.(1999). Diagnosis of polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am.28(2):397–408.
17. Laven, J.S., Mulders, A.G., Visser, J.A., Themmen, A.P., De Jong, F.H. and Fauser, B.C.(2004): Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endocrinol. Metab. 89 :318–323.
18.Agarwal, S.K., Judd, H.L, and Magoffin, D.A. (1999). A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J. Clin. Endocrinol. Metab, 81:3686–3691
19. Carmina, E., Rosato, F., Janni, A., Rizzo, M and Longo R.A. (2006). Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J. Clin. Endocrinol. Metab.91:2–6.
20. Allahbadia, G.N .and Merchant, R.(2011). Polycystic ovary syndrome and impact on health. Mid. East Fert. Societ: 16:19–37.
21. Mc Cartney, C.R., Eagleson, C.A., and Marshall ,J. C.(2002). Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. Semin. Reprod. Med. 20:317–336.
22. Taylor, A.E., McCourt, B., and Martin, K.A.(1997). Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:2248–2256.
23. Begawy A.F., El-Mazny ,A .N., Abou-Salem ,N.A., and El-aweel.N.E. (2010) . Anti-Mu¨ llerian hormone in polycystic ovary syndrome and normo-ovulatory women: Correlation with clinical, hormonal and ultrasonographic parameters . Mid. East Fert. Soci. J. 15:253–258
24. Ehremaan, D.A. and Rosen field, R.L. (1992). Detection of functional ovarian hyperandrogenism in women with androgen excess .Nat. Engl. J. Med. 291:157-162.
25.Urbanek,M.,Lergo.R.S.,Driscoll.D.A.,Azziz.R., Ehrmann. D. A. ,Norman, et al. (1999).Thirty seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. Proc. Natl. Acad.Sci.96 :8573-8578.
26. Arroyo, A., Laughlin, G.A, Morales, A.J and Yen, S.S. (1997). Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J .Clin. Endocrinol. Metab ;82:3728–3733.
27.Ganie,M.A., Laway, B.A., Wani, T.A., Zargar, M.A., Nisar, S . Ahamed ,F .and Khurana, M. L. (2011). Association of subclinical hypothyroidism and phenotype, insulin resistance, and lipid parameters in young women with polycystic ovary syndrome. Fertil. Steril. 95( 6):1-5
28. Dittrich, R., Kajaia , N ., Cupisti, S ., Hoffmann, I., Beckmann, M. and Mueller, A.(2009).Association of thyroid-stimulating hormone with insulin resistance and androgen parameters in women with PCOS. Repro. Bio .Med. 19(3):319-325.
29. Beydoun, H., Stadtmauer,L .,Russell, H., Zhaol, Y and Oehninger, S .(2009).Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies . Repro. Bio Med. Online. 18(6):856-863
30. Liou, T., Yang, J., Hsieh, C., Lee, C., Hsu,C., and Hsu, M. ( 2009 ). Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women . Fertil & Steril . 92(6), Pp1960-1965.
31. Benson, S. ,Janssen, O. E., Hahn, S., Tan, S., Dietz, T. and Man, K.(2008). Obisity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain, behave.& immune. 22:177-184.
32. Wang, J. X., Davies, M. J., and Norman, R. J.(2001). Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum. Reprod. 16:2606–2609.
33. Chang. R. J.(2004). A practical approach to the diagnosis of polycystic ovary syndrome. Amer .J. Obst. Gynecol. 191:713–717 .
34. Siegel, S., Futterweit, W. and Davies, T.F.( 2002). A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil. Steril. 78:1240-1243.
35. Freytag, U. (2003): Subcutaneous adipose tissue pattern in lean and obese women with PCOS. Diploma thesis-Francens-University Mader, S.S. (2004). Understanding Human Anatomy and Physiology. (5th .ed). M cCraw-Hill.Pp:1-443.
36. Deugarte, C.M., Woods, K.S., Bartolucci, A.A., and Azziz, R. (2006). Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J. Clin. Endocrinol. Metab. 91:1345–1350.
37. Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J, and Stephens, K.C. (2004). Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab.;89: 453–462.
38. Ovalle, F., and Azziz, R. (2002). Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fert. Steril. 77(6): 1095-1105.
39.Ovalle .F., and Azziz. R. (2002). Insulin resistance, polycystic ovary syndrome and type 2 diabetes mellitus. Fert and Steril. 77(6): Pp1095-1105.